The MolecuLight i:X from MolecuLight, a company out of Toronto, Canada, is finally launching in Europe following CE Mark approval of the device more than a year ago. Smith & Nephew will be distributing the device, which allows clinicians to spot bacteria directly on the wound using fluorescence visualization that doesn’t require the use of any contrast agent. It gives the ability to assess the bacterial burden, measure the wound area, and document it in a variety of ways.
These days, most wound assessment happens visually, typically without being able to spot most bacterial loads. Swabs are used to identify bacteria, and even that can be a hit and miss, as a lot of wounds have areas that are less infected than others.
The MolecuLight i:X is used in a darkened room while it illuminates the wound using its special blacklight, while other images can be acquired with the room lights on. The device can then help generate outlines of the wound and provide automatic area measurements. Additionally, it can help guide where to swab the wound to best sample it for bacteria.
In clinical studies, the MolecuLight i:X has already shown the ability to improve healing rates, detect subsurface bacterial infestations, and spot overall high levels of bacteria.
Here’s a promo video demonstrating how to use the MolecuLight i:X:
Product page: MolecuLight i:X…
Flashbacks: CE Mark Approval for Moleculight i:X Wound Imaging Device Initiates Product Commercialization in the EU; Health Canada Approval for MolecuLight i:X Marks Significant Clinical Advancement in Wound Care Diagnosis